Glial fibrillary acidic protein and neurofilament light chain as biomarkers in pediatric multiple sclerosis.
Laura SaucierBrian C HealyShrishti SaxenaEunnindy SanonTanuja ChitinisPublished in: Multiple sclerosis journal - experimental, translational and clinical (2024)
sNfL and sGFAP are elevated in POMS compared to PHC. Both biomarkers are associated with clinical disability. Elevated sGFAP may reflect early neurodegeneration in POMS, while sNfL reflects disease activity and DMT response. Elevated sNfL among some clinically and radiographically stable POMS patients suggests ongoing neuroaxonal injury with a potential role for sNfL monitoring disease stability.
Keyphrases
- multiple sclerosis
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- end stage renal disease
- rheumatoid arthritis patients
- ejection fraction
- newly diagnosed
- ankylosing spondylitis
- chronic kidney disease
- peritoneal dialysis
- juvenile idiopathic arthritis
- patient reported outcomes
- ionic liquid
- neuropathic pain
- protein protein
- amino acid